These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6613192)

  • 1. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus].
    Müller G; Biering A; Lux E; Richter V
    Z Gesamte Inn Med; 1983 May; 38(10):282-4. PubMed ID: 6613192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 6. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunochemical study of the alpha 2-glycoprotein from the atherosclerotically altered aortic wall in the blood serum of ischemic heart disease patients].
    Murashko VV; Baranov AP; Kamenets AV; Tatarinov IuS; Chekhonin VP
    Ter Arkh; 1985; 57(9):37-9. PubMed ID: 2417347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of anti-elastin peptide antibodies in normal and arteriosclerotic human sera by ELISA.
    Fulop T; Jacob MP; Robert L
    J Clin Lab Immunol; 1989 Oct; 30(2):69-74. PubMed ID: 2641531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very low density lipoprotein (VLDL) pattern in primary hyperlipoproteinaemia type IIb and type IV.
    Kłosiewicz-Latoszek L; Naruszewicz M; Cybulska B; Szostak WB; Chotkowska E
    Mater Med Pol; 1979; 11(3):230-4. PubMed ID: 232894
    [No Abstract]   [Full Text] [Related]  

  • 11. [Platelet aggregation in hyperlipoproteinemias].
    Calabrese S; Da Col PG; Giansante C; Morgante O; Cattin L
    Minerva Med; 1982 May; 73(22):1541-6. PubMed ID: 7088380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative burst and lysosomal enzyme release by polymorphonuclear cells in type IIa, type IIb and type IV primary hyperlipoproteinaemia.
    Ventura MT; Puzziferri I; Tortorella C; Resta F; Capurso A; Antonaci S
    Recenti Prog Med; 1993; 84(7-8):503-10. PubMed ID: 8356303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of coagulation, atherosclerosis, and arterial thrombosis.
    Conard J; Samama MM
    Semin Thromb Hemost; 1986 Apr; 12(2):87-90. PubMed ID: 3755552
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

  • 16. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 17. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of elastin peptides in normal and arteriosclerotic human sera by ELISA.
    Fülöp T; Wei SM; Robert L; Jacob MP
    Clin Physiol Biochem; 1990; 8(6):273-82. PubMed ID: 2132161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
    Paragh G; Balogh Z; Boda J; Mohácsi A; Juhász A; Leövey A
    Orv Hetil; 1993 Jan; 134(3):121-4. PubMed ID: 8421622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.